Eagle Vision Pharmaceutical Corporation is developing novel agents that enhance the power of Magnetic Resonance Imaging (MRI) to revolutionize the diagnosis and management of heart disease and cancer. Eagle Vision's cardiac-specific SeeMoreTM is the first imaging agent harnessing the power of MRI to provide results in three critical areas: cardiac perfusion, cardiac function and cardiac vessel status, which today require multiple tests and cost thousands of dollars. SeeMore makes possible a safe and effective one-stop procedure that both provides significant cost savings and produces cardiac perfusion images that are significantly sharper and clearer than those available today-providing cardiologists with comprehensive information for the diagnosis and treatment of cardiovascular disease. SeeMore addresses multi-billion dollar market segments for MRI and cardiac perfusion imaging that are growing at double digit annual rates and generate pharmaceutical-level returns, but involve significantly lower technical risk. FDA clearance to begin Phase II was received in 2005 and the Phase II trial is underway. The company also is developing the imaging agent for use in diagnosing and monitoring the treatment of hepatic cancer.
